drugset / Trial / NCT04020588

Anti-inflammatories and Adolescent Schizophrenia

NCT04020588

RandomizedParallel-groupDouble-blindTreatment

Summary

A double-blind controlled trial assessing the efficacy of anti-inflammatories on symptoms and cognition of adolescents with schizophrenia

Timeline

Start
2019-02-25
Primary completion
2020-06
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 200 mg Oral
Comparator Minocycline Small molecule 100 mg Oral

Indications